Johnson & Johnson (JNJ) closed at $267.14 on November 19, 2026, down 2.0% from the previous close, on volume of 8,940,587 shares (30-day average 7,746,779).
Data as of November 19, 2026.
19-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 23, 2026 | Put Spread | 30-Oct-26255 : 260 P | 21,820 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 19, 2026. See the largest for 5, 30, 60 and 90 days
PRNewswire (Fri, 20-Nov 8:00 AM ET)
Dow drops below 50K for the first time in 5 months
Seeking Alpha News (Thu, 19-Nov 3:24 PM ET)
Business Wire (Thu, 19-Nov 8:51 AM ET)
PRNewswire (Thu, 19-Nov 8:02 AM ET)
Fate of Trump's new FDA commissioner nominee will fall on Senate Democrats
Seeking Alpha News (Wed, 18-Nov 10:22 AM ET)
Trump abandons Heidi Overton as FDA commissioner nominee: reports
Seeking Alpha News (Tue, 17-Nov 10:17 PM ET)
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks (Tue, 17-Nov 8:50 AM ET)
White House getting antsy over FDA commissioner nominee Heidi Overton
Seeking Alpha News (Mon, 16-Nov 5:32 PM ET)
Business Wire (Mon, 16-Nov 8:00 AM ET)
M&A News: Johnson & Johnson Has $3.4B Eye Biotech Ollin Biosciences in Its Sights
TipRanks (Mon, 16-Nov 6:54 AM ET)
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
Johnson & Johnson trades on the NYSE stock market under the symbol JNJ.
As of November 19, 2026, JNJ stock price declined to $267.14 with 8,940,587 million shares trading.
JNJ has a beta of -0.40, meaning it tends to be less sensitive to market movements. JNJ has a correlation of 0.04 to the broad based SPY ETF.
JNJ has a market cap of $643.28 billion. This is considered a Mega Cap stock.
Last quarter Johnson & Johnson reported $25 billion in Revenue and $2.59 earnings per share. This beat revenue expectation by $5 million and exceeded earnings estimates by $.06.
In the last 3 years, JNJ traded as high as $290.25 and as low as $140.68.
The top ETF exchange traded funds that JNJ belongs to (by Net Assets): VOO, VTI, IVV, SPY, VTV.
JNJ has outperformed the market in the last year with a price return of +34.5% while the SPY ETF gained +9.2%. JNJ has also outperformed the stock market ETF in the last 3 month and 2 week periods returning -1.8% and -1.9%, respectively, while the SPY returned -6.7% and -2.3%, respectively.
JNJ support price is $267.74 and resistance is $277.66 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that JNJ shares will trade within this expected range on the day.